Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. The Lancet. Oncology Moreau, P. n., Kumar, S. K., San Miguel, J. n., Davies, F. n., Zamagni, E. n., Bahlis, N. n., Ludwig, H. n., Mikhael, J. n., Terpos, E. n., Schjesvold, F. n., Martin, T. n., Yong, K. n., Durie, B. G., Facon, T. n., Jurczyszyn, A. n., Sidana, S. n., Raje, N. n., van de Donk, N. n., Lonial, S. n., Cavo, M. n., Kristinsson, S. Y., Lentzsch, S. n., Hajek, R. n., Anderson, K. C., João, C. n., Einsele, H. n., Sonneveld, P. n., Engelhardt, M. n., Fonseca, R. n., Vangsted, A. n., Weisel, K. n., Baz, R. n., Hungria, V. n., Berdeja, J. G., Leal da Costa, F. n., Maiolino, A. n., Waage, A. n., Vesole, D. H., Ocio, E. M., Quach, H. n., Driessen, C. n., Bladé, J. n., Leleu, X. n., Riva, E. n., Bergsagel, P. L., Hou, J. n., Chng, W. J., Mellqvist, U. H., Dytfeld, D. n., Harousseau, J. L., Goldschmidt, H. n., Laubach, J. n., Munshi, N. C., Gay, F. n., Beksac, M. n., Costa, L. J., Kaiser, M. n., Hari, P. n., Boccadoro, M. n., Usmani, S. Z., Zweegman, S. n., Holstein, S. n., Sezer, O. n., Harrison, S. n., Nahi, H. n., Cook, G. n., Mateos, M. V., Rajkumar, S. V., Dimopoulos, M. A., Richardson, P. G. 2021; 22 (3): e105–e118

Abstract

This Policy Review presents the International Myeloma Working Group's clinical practice recommendations for the treatment of relapsed and refractory multiple myeloma. Based on the results of phase 2 and phase 3 trials, these recommendations are proposed for the treatment of patients with relapsed and refractory disease who have received one previous line of therapy, and for patients with relapsed and refractory multiple myeloma who have received two or more previous lines of therapy. These recommendations integrate the issue of drug access in both low-income and middle-income countries and in high-income countries to help guide real-world practice and thus improve patient outcomes.

View details for DOI 10.1016/S1470-2045(20)30756-7

View details for PubMedID 33662288